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Abstract
Objectives Evaluate test-retest repeatability, ability to discriminate between osteoarthritic and healthy participants, and sensitiv-
ity to change over 6 months, of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) biomarkers in knee OA.
Methods Fourteen individuals aged 40–60 with mild-moderate knee OA and 6 age-matched healthy volunteers (HV) underwent
DCE-MRI at 3 T at baseline, 1 month and 6 months. Voxelwise pharmacokinetic modelling of dynamic data was used to calculate
DCE-MRI biomarkers including Ktrans and IAUC60. Median DCE-MRI biomarker values were extracted for each participant at each
study visit. Synovial segmentation was performed using both manual and semiautomatic methods with calculation of an additional
biomarker, the volume of enhancing pannus (VEP). Test-retest repeatability was assessed using intraclass correlation coefficients
(ICC). Smallest detectable differences (SDDs) were calculated from test-retest data. Discrimination between OA and HVwas assessed
via calculation of between-group standardised mean differences (SMD). Responsiveness was assessed via the number of OA partic-
ipants with changes greater than the SDD at 6 months.
Results Ktrans demonstrated the best test-retest repeatability (Ktrans/IAUC60/VEP ICCs 0.90/0.84/0.40, SDDs as % of OA mean
33/71/76%), discrimination between OA and HV (SMDs 0.94/0.54/0.50) and responsiveness (5/1/1 out of 12 OA participants
with 6-month change > SDD) when compared to IAUC60 and VEP. Biomarkers derived from semiautomatic segmentation
outperformed those derived from manual segmentation across all domains.
Conclusions Ktrans demonstrated the best repeatability, discrimination and sensitivity to change suggesting that it is the optimal
DCE-MRI biomarker for use in experimental medicine studies.
Key Points
• Dynamic contrast-enhanced MRI (DCE-MRI) provides quantitative measures of synovitis in knee osteoarthritis which may
permit early assessment of efficacy in experimental medicine studies.
• This prospective observational study compared DCE-MRI biomarkers across domains relevant to experimental medicine: test-
retest repeatability, discriminative validity and sensitivity to change.
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• The DCE-MRI biomarker Ktrans demonstrated the best performance across all three domains, suggesting that it is the optimal
biomarker for use in future interventional studies.
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Abbreviations
DCE Dynamic contrast-enhanced
GBCA Gadolinium-based contrast agent
KOOS Knee injury and osteoarthritis outcome score
OA Osteoarthritis
SDD Smallest detectable difference
SPGR Spoiled gradient echo
VEP Volume of enhancing pannus
Introduction
Inflammation of the synovial membrane (synovitis) is
common in OA, with MRI-detected synovitis occurring
in up to 90% of OA knees [1, 2]. It can be detected, both
histologically and on imaging, from the early stages of the
disease [3]. Strong cross-sectional associations exist be-
tween the presence of synovitis and the severity of knee
pain [2]. Longitudinal associations have been demonstrat-
ed between the presence and severity of synovitis and
both symptomatic and structural OA progression [4–6].
There is therefore a strong rationale for therapeutic
targeting of synovitis to provide disease modification,
particularly in patients with mild to moderate disease
where disease-modifying and regenerative approaches
are targeted [7].
Dynamic contrast-enhanced magnetic resonance imag-
ing (DCE-MRI) aims to characterise the uptake and wash-
out of gadolinium-based contrast agents (GBCA) in tis-
sues of interest, providing biomarkers of tissue perfusion,
capillary permeability and blood and interstitial volume.
These parameters are known to change in the synovium in
OA [8]. DCE-MRI has been used to assess synovitis in
early-phase clinical trials of rheumatoid arthritis and has
demonstrated superiority over semiquantitative assess-
ments in this setting [9, 10]. The promise of DCE-MRI
in OA has been illustrated by several studies demonstrat-
ing changes in DCE-MRI biomarkers following intra-
articular corticosteroid treatment with improved respon-
siveness compared to alternative semiquantitative and
qualitative assessments of synovitis [11, 12].
DCE-MRI biomarkers are of particular interest in
early-phase experimental medicine studies which aim to
establish early proof-of-concept evidence of efficacy of
novel treatments, streamline the treatment development
process and reduce late-stage failure rates. They could
improve outcome assessment in studies of synovitis-
targeted therapies by quantifying response to treatment
and are likely to be more robust than relying on qualita-
tive or semiquantitative assessment. There may also be a
role in selecting which patients are suitable for entry into
studies of synovitis-targeted treatments.
However, to increase confidence in the utility of DCE-MRI
biomarkers in these settings, technical and clinical validation
is essential [13]. This includes an assessment of test-retest
repeatability, ability to discriminate between knee OA and
normal ageing and expected changes over relevant follow-up
periods.
Therefore, the purpose of this study was to evaluate the
test-retest repeatability, ability to discriminate between osteo-
arthritic and healthy participants and sensitivity to change
over 6 months, of DCE-MRI biomarkers in knee OA.
Methods
Participants
The study was approved by the local research ethics com-
mittee, and written informed consent was given by all
participants. This was a single-centre, prospective experi-
mental feasibility study where DCE-MRI was the
intervention.
Participants with mild-moderate knee osteoarthritis
(OA) were recruited from specialist orthopedic knee
clinics at a university teaching hospital. Healthy volun-
teers (HV) approximately matched for age were recruited
via paper and electronic advertisement materials and from
a register of healthy individuals who had agreed to be
contacted about research studies. Inclusion criteria for
OA participants were (i) age 40–60 years, (ii) body mass
index (BMI) of ≤ 35 kg/m2, (iii) clinical diagnosis of knee
OA per the American College of Rheumatology criteria
and (iv) mild-moderate radiographic OA defined as
Kellgren-Lawrence grade 2 or 3 on a postero-anterior
fixed flexion knee radiograph taken using a positioning
device (SynaFlexer; BioClinica) with medial compartment
predominant disease [14–16]. Exclusion criteria were any
history of previous lower limb fracture, previous knee
surgery (including arthroscopy), history of inflammatory
arthritis or contraindication to MRI or GBCA administra-
tion (e.g. pacemaker, renal failure). For HV participants,
inclusion criteria were (i) age 40–60 years, (ii) no current
or significant previous symptoms of knee pain or stiffness
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and (iii) BMI ≤ 35 kg/m2. At each study visit, participants
completed the knee injury and osteoarthritis outcome
score (KOOS) to assess symptoms and had their BMI
recorded. No disease-modifying intervention was received
by any participant during the study follow-up period.
Image acquisition
Participants underwent MRI of a single knee (most symptom-
atic knee in OA participants, randomly selected knee in HV
using a random number generator [www.random.org]) on a 3
T platform (GE 750; GE Healthcare) using an 8-channel
transmit/receive knee coil (InVivo). Imaging was performed
at baseline and 6-month follow-up. A subset of participants
(10 OA, 6 HV) was asked to return for imaging at 1-month
post baseline for assessment of test-retest repeatability.
Participants were supine and their knee was positioned in
the coil with padding and foot support to minimise subject
motion.
All MRI sequence parameters are provided in Table 1 with
further details in the Supplementary Materials.
Image analysis—pharmacokinetic modelling
Voxelwise pharmacokinetic modelling of DCE-MRI data was
performed on registered images (Supplementary Materials)
using the extended Tofts compartmental model [17] with a
population-averaged arterial input function (AIF) [18]. All
AIFs were corrected for individual patient haematocrit [19].
GBCA concentration was estimated from the change in signal
relaxation due to the presence of GBCA (gadoterate
[Dotarem]; Guerbet) compared to the native T1 values using
a relaxivity of 3.5 L.mmol-1.s-1[20]. Native T1 values were
calculated from the variable flip angle images acquired before
the contrast agent injection [21]. The biomarkers extracted
were Ktrans (units min-1), the volume transfer constant for con-
trast agent between blood plasma and extravascular extracel-
lular space; vp, fractional volume of blood plasma; ve, the
fractional volume of extravascular extracellular space; and
IAUC60 (mM.s), the initial area under the contrast agent con-
centration time curve 60-s post contrast agent arrival in the
tissue.
Image analysis—region of interest definition
Two alternative methods of region of interest (ROI) definition
were evaluated involving manual and semiautomatic ap-
proaches. Manual segmentation of the synovium was per-
formed on the post-contrast 3D fat-suppressed spoiled gradi-
ent echo (FS SPGR) sequence by a musculoskeletal radiolo-
gist with 6 years’ experience (J.M.), with definition of seven
synovial ROIs: suprapatellar, Hoffa’s fat pad, medial and lat-
eral perimeniscal, intercondylar notch, medial and lateral pos-
terior femoral condyles (Fig. 1). Anatomical definitions of
synovial ROIs are provided in Table 2. The manual segmen-
tation was intended to provide a rough estimation of where the
synovium was located, rather than a detailed slice-by-slice
manual segmentation.
For semiautomatic segmentation, enhancing voxels
were defined by subtracting the pre-contrast 3D FS
SPGR sequence from the matching post-contrast sequence
using a shuffle transform [22]. For a given voxel in the
Table 1 Selected MRI sequence












3D SPGR FS 12/3.6 15 384 × 384a 320 × 320 2c 0.5
T1 mapping 3D SPGR 4/2.4 2/6/14 128 × 128
b 320 × 320 4d 3
Dynamic series
(35 phases)












2500/36 90 384 × 256 160 × 160 3 ( 1-mm
gaps)
3
Abbreviations:MOAKS, MRI osteoarthritis knee score; SPGR, spoiled gradient echo; IW, intermediate-weighted;
FS, fat-saturated; TR, repetition time; TE, echo time; FA, flip angle; FOV, field-of-view; NEX, number of
excitations
a Interpolated to 512 × 512 with zero filling
b Interpolated to 256 × 256 with zero filling
c Interpolated to 1 mm with zero filling
d Interpolated to 2 mm with zero filling
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post-contrast image, the shuffle transform minimises the
absolute difference between the signal intensity of that
voxel and the corresponding voxel plus a defined
neighbourhood (for this study the adjacent 3 × 3 voxels)
in the pre-contrast image. This improves the quality of the
subtracted images and is also robust to residual motion
artefact following image registration (Fig. 2). The
shuffle-subtracted images were then converted to binary
enhancing masks using the Otsu thresholding [23]. The
intersection between this binary mask and the manual
segmentation was termed the ‘volume of enhancing
pannus’ (VEP) mask. The VEP mask was used for the
extraction of median DCE-MRI biomarker values for each
synovial ROI and for the whole joint (all ROIs com-
bined). In addition, the VEP mask was used to create an
estimate of volume of synovial tissue (VEP, measured in
mL) by multiplying the number of voxels included in the
VEP mask by the voxel size.
Segmentation was repeated by the original observer
with an interval of > 6 months between analyses and an
independent second observer (T.R., a radiology resident
with 4 years’ experience) for all baseline visits to enable
assessment of intra and inter-observer reproducibility of
DCE-MRI biomarkers.
Image analysis—semiquantitative grading
Semiquantitative grading of synovitis was performed using
the MRI Osteoarthritis Knee Score (MOAKS) by a musculo-
skeletal radiologist with 6 years’ experience (J.M.) [24].
MOAKS grades synovitis in two ways: signal alterations in
Hoffa’s fat pad (Hoffa synovitis) and degree of suprapatellar
joint effusion (effusion-synovitis). Both are scored on a 4-
point ordinal scale (0–3). The intra and inter-reader reproduc-
ibility of MOAKS have previously been published [24].
Statistics (see Supplementary Material for detail)
Test-retest repeatability was assessed using baseline and
1-month whole joint data with calculation of the intraclass
correlation coefficient (ICC). Intra- and inter-observer re-
producibility was assessed using the root-mean-square co-
efficient of variation (RMSCV) and the concordance cor-
relation coefficient (CCC). We also calculated the
smallest detectable difference (SDD), representing the
magnitude of change that would give 95% confidence of
a change being genuine rather than due to measurement
noise, assuming identical measurement conditions. This is




× 1.96) times the test-retest within-
subject standard deviation or within-subject coefficient of
variation (dependent on correlation between magnitude
and variability of the biomarker) and is also known as
the repeatability coefficient (RC) [25].
Discrimination between OA and HV participants was
assessed using baseline data. Descriptive statistics were calcu-
lated for each group, and the standardised mean difference
(SMD) was estimated for each DCE-MRI biomarker by divid-
ing the difference in mean between the two groups by the
pooled standard deviation.
Table 2 Anatomical definition of
synovial regions of interest Region Definition
Suprapatellar From mid pole of the patella to the superior extent of the suprapatellar bursa,
including medial and lateral peripatellar recesses
Hoffa fat pad From the junction of patellar tendon/tibial tuberosity to mid pole of patella superi-
orly. Posteriorly extends to the anterior aspect of intermeniscal ligament and
anterior horns of medial/lateral menisci.
Medial perimeniscal Wraps around medial meniscus. Extends superiorly deep to the medial collateral
ligament (MCL) to the level of femoral MCL origin. Extends inferiorly deep to
MCL to tibial MCL attachment.
Lateral perimeniscal Wraps around lateral meniscus. Extends superiorly deep to lateral collateral
ligament complex to fibular collateral ligament femoral origin. Extends inferiorly
to level of tibiofibular joint. Includes popliteus recess, if present.
Intercondylar notch From the superior aspect of anterior cruciate ligament (ACL) femoral origin to the
floor of the intercondylar notch at intercondylar eminences. Posterior margin
tangential to the most posterior aspect of posterior cruciate ligament, anterior
margin at anterior aspect of ACL.
Posterior medial femoral
condyle
From most proximal aspect of the medial head of gastrocnemius tendon to superior
border of the posterior horn of the medial meniscus. Extends to meet
intercondylar notch region laterally and medial perimeniscal region medially.
Includes semimembranosus/medial head of gastrocnemius bursa, if present.
Posterior lateral femoral
condyle
From most proximal aspect of the lateral head of gastrocnemius tendon to superior
border of the posterior horn of the lateral meniscus. Extends to meet intercondylar
notch region medially and lateral perimeniscal region laterally.
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Six-month changes in each biomarker were assessed
using descriptive statistics. The number of participants
with changes in each biomarker greater than the SDD
was calculated.
No formal sample size calculation was performed for this




Fourteen OA and six HV participants were recruited. Baseline
characteristics are provided in Table 3. Eight OA and six HV
participants completed the 1-month visit. Twelve OA
participants and five HV completed the 6-month visit. The
reasons for the lost to follow-up were the inability to schedule
the MR examination in the appropriate time window (n = 2)
and participant withdrawal (n = 1).
Test-retest repeatability
Repeatability metrics values for each parameter are pro-
vided in Table 4. Variabilities of Ktrans, IAUC60 and
VEP were not significantly correlated with the value
of the biomarker, so wSD and absolute SDD values
are presented. Variabilities of vp and ve were significant-
ly correlated with biomarker value, so wCV and per-
centage SDD values are presented. Kendall’s τ correla-
tion coefficients for baseline and 1-month biomarker
values are provided in Supplementary Table 1. Due to
Fig. 1 3D rendering of synovial
regions of interest with anterior
(a), posterior (b), medial (c) and
lateral (d) views. 3D rendering of
femur, tibia and patella (grey)
provided for reference. ROI Key:
green—suprapatellar, yellow—








the poor repeatability of vp and ve and the presence of
physiologically implausible values (e.g. ve greater than
1), these biomarkers were not used for further analyses.
Repeatability of biomarker measurements from semiau-
tomatic segmentation (VEP mask) was better than those
derived from manual segmentation for K trans and
IAUC60. Measurements derived from semiautomatic seg-
mentation were therefore preferred for all subsequent
analyses.
Intra- and inter-observer reproducibility
Intra and inter-observer reproducibilitywas best forKtrans derived
from semiautomatic segmentation (both RMSCV 2.1%, CCC
[95% CI] 1.00 [1.00, 1.00]). Ktrans and IAUC60 derived from
semiautomatic segmentation demonstrated improved
reproducibility compared to manual segmentation. All intra-
and inter-observer reproducibility data are provided in Table 4.
Discriminative ability
Baseline between-group differences for the whole joint are
illustrated in Fig. 3. Plots for individual ROI are provided in
Supplementary Figure 1. One HV participant hadmuch higher
values of Ktrans and IAUC60 than other HV participants (> 5
SD greater than mean HV value excluding this participant)
across all ROIs. On further investigation, it was determined
that this HV had taken part in karate practice the night before
each of the three study visits and also had an undisclosed
history of gout (never having affected the knee). Possible ex-
planations considered for this value were that this represented
part of the normal range of healthy values, or that the presence
Fig. 2 Example of the use of
shuffle transform to improve
quality of subtracted image
compared to simple subtraction of
registered images. a pre-contrast
3D FS SPGR, b post-contrast 3D
FS SPGR, c simple subtraction
(following intensity-based regis-
tration), d shuffle subtraction.
Improved subtraction quality is
seen when the shuffle transform is
used
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of gout or recent intense physical activity had confounded
measurement. This participant’s data were not excluded be-
cause the participant met the pre-specified inclusion criteria,
but, where appropriate, additional exploratory analyses ex-
cluding this participant’s data are reported.
SMDs between OA and HV groups were 0.94, 0.54 and
0.50 for Ktrans, IAUC60 and VEP respectively. Excluding the
outlier HV case, SMDs were 1.34 for Ktrans and 1.12 for
IAUC60. Visual analysis of plots for individual synovial
ROIs (Supplementary Figure 1) revealed the highest
between-group differences for the intercondylar notch and
medial and lateral perimeniscal ROIs for Ktrans and IAUC60.
The largest between-group difference and between-subject
variability for VEP were seen in the suprapatellar ROI, as
would be expected given the distensibility of the suprapatellar
pouch to accommodate varying degrees of joint effusion.
Discriminative ability was better in all cases for measurements
derived from semiautomatic segmentation than for manual
segmentation-derived measurements.
Sensitivity to change over 6 months
Changes in DCE-MRI biomarkers over 6 months are
summarised in Fig. 4, with data for all synovial ROIs provided
in Supplementary Figure 2.
ForKtrans, 5 out of 12OA and 1 out of 5HVparticipants had 6-
month changes exceeding the SDD. For both IAUC60 andVEP, 1
out of 12 OA and no HV participants had changes exceeding the
SDD. Using biomarkers extracted from manual segmentation
rather than semiautomatic segmentation, 2 out of 12 OA partici-
pants and no HV participants had 6-month changes in Ktrans ex-
ceeding the SDD, and no participants had 6-month changes in
IAUC60 greater than the SDD. Representative images of partici-
pants with changes greater than the SDD are provided in Fig. 5.
A comparison of 6-month changes in Ktrans and semiquan-
titative MOAKS synovitis score (sum of effusion-synovitis
and Hoffa synovitis scores, scale 0–6) is provided in Fig. 6.
Table 3 Participant characteristics at baseline. The Knee injury and
Osteoarthritis Outcome Score (KOOS) is a validated patient-reported
outcome measure which assesses knee pain and symptoms as well as
the impact on knee-related activities of daily living, sports and recreation
and quality of life. Scores range from 0 to 100, with 0 indicating the most
severe symptoms possible and 100 indicating no symptoms
Group
OA (n = 14) HV (n = 6)
Age (years)a 51 (5) 55 (4)
Sex (M:F) 8:6 2:4
BMI (kg/m2)a 29.2 (4.1) 29.7 (3.0)
K-L grade (2:3) 10:4 N/A
KOOS paina 60 (20) 98 (2)
KOOS symptomsa 56 (19) 96 (5)
KOOS ADLa 67 (21) 99 (1)
KOOS sportsa 36 (23) 94 (7)
KOOS QoLa 33 (23) 95 (8)
Abbreviations: BMI, body mass index; K-L, Kellgren-Lawrence; ADL,
activities of daily living; QoL, quality of life
aMean (SD)





















Ktrans (min-1) Manual 2.1 × 10-5 1.3 × 10-5 0.62 (0.14, 0.86) 0.004 0.010 0.020 (50) 3.0 0.99 (0.98,1.00) 3.0 0.99 (0.98,1.00)
Semiauto 2.1 × 10-4 2.4 × 10-5 0.90 (0.71, 0.97) 0.005 0.013 0.039 (33) 2.1 1.00 (1.00,1.00) 2.1 1.00 (1.00,1.00)
IAUC60 (mM.s) Manual 4.2 2.4 0.64 (0.18, 0.87) 1.54 4.26 4.71 (90) 3.4 0.99 (0.99,1.00) 3.2 1.00 (0.99,1.00)
Semiauto 31.7 5.9 0.84 (0.58, 0.95) 2.43 6.74 9.47 (71) 2.4 1.00 (1.00,1.00) 2.4 1.00 (1.00,1.00)
Synovial volumec (mL) Manual 9845 820 0.92 (0.57, 0.98) 8.5% 23.5% 394 (NA)b 8.1 0.94 (0.85, 0.98) 16.1 0.74 (0.53, 0.87)
Semiauto 474.5 667.0 0.40 (0, 0.75) 24.8 68.8 90.3 (76) 9.4 0.95 (0.88, 0.98) 9.1 0.94 (0.86, 0.97)
vp Manual 4.1 × 10
-7 7.4 × 10-7 0.36 (0, 0.69) 134% 371% 3.0 × 10-4 (NA)b 5.5 1.00 (1.00,1.00) 9.1 0.99 (0.99, 1.00)
Semiauto 2.0 × 10-6 1.9 × 10-6 0.51 (0, 0.82) 152% 421% 5.4 (NA)b 11.7 1.00 (1.00,1.00) 6.0 1.00 (1.00,1.00)
ve Manual 0 0.04 0 (0, 0.53) 65% 180% 0.36 (NA)
b 7.0 0.97 (0.93, 0.98) 10.8 0.94 (0.88, 0.97)
Semiauto 0.70 0.67 0.51 (0, 0.82) 97% 268% 0.63 (NA)b 6.8 1.00 (0.99, 1.00) 6.2 1.00 (0.99, 1.00)
Abbreviations: Seg, segmentation; ICC, intraclass correlation coefficient; wSD, within-subject standard deviation; wCV, within-subject coefficient of
variation; SDD, smallest detectable difference; NA, not applicable, σ2b between-subject variance; σ
2
w within-subject variance; RMSCV, root mean square
coefficient of variation; CCC, concordance correlation coefficient
a Provided as absolute values for wSD and percentages for wCV, with SDD correspondingly presented as an absolute value or percentage
bMedian presented instead of mean as not normally distributed
c Synovial volume is synonymous with VEP for semiautomatic segmentation. Manual synovial volume includes both enhancing and non-enhancing
voxels.
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There was limited concordance between participants with
changes in Ktrans exceeding the SDD and participants with
changes in MOAKS synovitis score.
Discussion
This study suggests that Ktrans is the optimum of the evaluated
DCE-MRI biomarkers for use in experimental medicine stud-
ies, with the best test-retest repeatability, best discrimination
between OA and HV participants and greatest sensitivity to
change as judged by the number of participants showing de-
tectable changes over a 6-month period.
Several previous studies have used DCE-MRI to evaluate
synovitis in knee OA, including describing cross-sectional
associations with symptoms and longitudinal association with
response to treatment [12, 27]. Novel contributions of the
current work include (1) improved synovial segmentation
leading to more precise parameter estimates, (2) assessment
of test-retest repeatability which is required for the interpreta-
tion of change at an individual level, (3) assessment of inter-
observer reproducibility and (4) comparison of DCE-MRI
biomarker values between OA and healthy knees which is
needed to assess discriminative validity and also to inform
effect size estimations for interventional studies.
Biomarkers that assess the intensity of synovitis (Ktrans and
IAUC60) performed better than VEP, which reflects the extent
of synovitis, across all assessment domains. This finding
agrees with a previous knee OA study which suggested im-
proved sensitivity to change of ‘intensive’ vs ‘extensive’ bio-
markers of synovitis [12]. One possible explanation for the
superiority of intensive biomarkers is the fact that synovial
tissue may enhance despite not being actively inflamed, for
example in areas of fibrosis related to previous inflammation
[3]. The extensive biomarker can therefore be hypothesised to
measure both active and inactive disease. However, such areas
are likely to demonstrate different kinetic characteristics to
areas of active inflammation, allowing intensive biomarkers
to more accurately reflect disease activity at the time of the
scan. DCE-MRI biomarkers derived from semiautomatic seg-
mentation performed better than those derived from manual
segmentation across the majority of assessment domains.
Previous studies have demonstrated reduction in time taken
for analysis with semiautomatic approaches but with similar
repeatability and reproducibility to manual approaches [28,
29]. One plausible explanation for the demonstrated superior-
ity of our semiautomatic approach is the fact that we used
shuffle subtraction prior to our thresholding step, in contrast
to approaches which attempt to threshold from the post-
contrast images alone.
Fig. 3 BaselineDCE-MRI biomarker values. Black dots aremedian values, with interquartile range error bars. The outlier HV is indicated with a triangle
symbol (all other participants are circles)
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Interestingly, test-retest repeatability metrics for manual
synovial segmentation were better than those for the semiau-
tomatic approach. This probably relates to the fact that the
manual segmentation was created to provide a rough mask
of the location of the synovium which is then used by the
semiautomatic method to identify enhancing voxels within
the masked region. It is relatively straightforward for an expert
radiologist to provide this initial rough mask as evidenced by
the good intra and inter-observer reproducibility of manual
segmentation. However, the manual method does not capture
the variability in the volume of actual enhancing synovial
tissue, in contrast to the semiautomatic method. The volume
of enhancing synovial tissue (rather than the approximate re-
gion within which it is located) is more likely to undergo
biological variation during the test-retest interval. Intra-
observer reproducibility was similar for the two methods,
but with superior inter-observer reproducibility for semiauto-
matic segmentation.
The design of our study assumes a natural history of OA
with negligible change over one month (repeatability), but
with the possibility of disease progression over 6 months.
This is a short interval relative to the conventional concept
of OA as a slowly progressive condition developing and
progressing over years. However, experimental medicine
Fig. 4 Top panel: Change in DCE-MRI biomarker values over time.
Individual participant trajectories are displayed by partially transparent
coloured circles and lines. Black circles and lines represent group median
values (with IQR error bars). As for Fig. 3, the outlier HV is identified
with a triangle symbol. Bottom panel: Waterfall plots of individual par-
ticipant 6-month change in DCE-MRI biomarker values, ordered along
the x-axis by magnitude of 6-month change value. Dotted lines represent
+/-SDD
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studies are typically of short duration and so to be useful in
this setting, an imaging biomarker has to be sensitive enough
to detect changes over short intervals. We therefore chose a 6-
month interval as a reasonable trade-off between the require-
ments of experimental medicine studies against the expected
relatively slow change in disease.
There was a wide range of 6-month changes in DCE-MRI
biomarkers in both positive and negative directions in OA
participants. This may reflect the fluctuating nature of syno-
vitis in OA, which is well recognised clinically [30]. Several
participants demonstrated 6-month changes greater than the
SDD (particularly for Ktrans) suggesting that sensitivity to
change is adequate for experimental medicine studies per-
formed over this interval. A possible counter-argument is that
this sensitivity to change indicates that the background vari-
ability is too high to expect to be able to detect additive effects
of therapy. Moreover, more participants demonstrated signif-
icant decreases rather than significant increases inKtrans, likely
related to regression to the mean. However, it should be noted
that the majority of participants did not demonstrate signifi-
cant reductions in DCE-MRI biomarkers and typically had
higher values than age-matched controls suggesting that there
is potential for improvement in these biomarkers with treat-
ment. Moreover, the group mean 6-month changes in DCE-
Fig. 5 Example post-contrast 3D
FS SPGR images overlaid with
Ktrans data from participants with
increases (a) and decreases (b) in
Ktrans at 6 months which exceeds
the SDD. In a, note extruded me-
dial meniscus with cuff of adja-
cent synovitis (white arrow). At 6
months, the synovitis has in-
creased both in amount and in-
tensity. In b, note distention of
suprapatellar pouch (white arrow)
and synovitis adjacent to the an-
terior horn of lateral meniscus
(white arrowhead) at baseline,
with marked reduction at 6
months
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MRI biomarkers for OA participants was close to 0, after
adjustment for baseline values (data not shown). This suggests
that the effects of treatment may also be detectable at a group
as well as at an individual level.
Our results suggest that DCE-MRI biomarkers are likely to
be of use in experimental medicine studies featuring putative
anti-inflammatory and immunomodulatory disease-
modifying treatments. The data presented can be used to in-
form sample size calculation for further interventional studies.
For example, using the observed standard deviation of 6-
month change in Ktrans in this study (~ 0.015 min-1), a
group-averaged reduction of 50% of the difference between
OA and HV mean values (~ 0.01 min-1) could be detected
with 80% power and a type 1 error rate of 5% (one-sided)
with a sample size of 24 participants per group, assuming an
active treatment vs placebo repeated-measures study design.
This is a clinically feasible reduction relative to a previous
study of change in Ktrans following intra-articular steroid ad-
ministration [12].
Limitations of this study include the long test-retest interval
(1 month) relative to the time over which clinical fluctuations
in synovitis occur in OA. Therefore, the measured variability
is likely to include contributions from both methodological
and biological sources, and true methodological variability is
likely to be lower. A second limitation is that the results pre-
sented are from a single centre and obtained with meticulous
quality control; therefore, extrapolation to multi-centre studies
should be done with caution. However, previous work sug-
gests that DCE-MRI biomarkers can be used in such a setting
with appropriate training, calibration and quality control [31].
In particular, the use of a semiautomated pipeline as described
in this study for defining the synovial ROI is likely to improve
robustness in the multi-centre setting compared with manual
methods [32]. Finally, the number of included participants
was low. While this was to some extent limited intentionally
to mimic the conditions of an experimental medicine study, it
does limit the precision of biomarker performance metric es-
timates. There is no ‘magic number’ of participants required
for a repeatability study [25]. However, we would contend
that the uncertainty in our repeatability estimates is low
enough to allow them to be used for sample size calculation
and interpretation of change at the individual level in future
interventional studies.
In conclusion, this study has assessed the test-retest repeat-
ability, discrimination between OA and ‘normal’ tissue char-
acteristics and sensitivity to change of DCE-MRI biomarkers.
Ktrans demonstrates the best performance across these domains
and is therefore the most likely to be useful in experimental
medicine studies and other future therapeutic trials.
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